<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03095885</url>
  </required_header>
  <id_info>
    <org_study_id>ALLN-177-204</org_study_id>
    <nct_id>NCT03095885</nct_id>
  </id_info>
  <brief_title>A Pilot Study of Oxalate Absorption in Secondary Hyperoxaluria</brief_title>
  <official_title>A Pilot Study of Oxalate Absorption in Secondary Hyperoxaluria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allena Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allena Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Identify individuals with greater absorption of oxalate based on increase in urinary oxalate
      excretion in response to a controlled oxalate-rich test meal.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a prospective 4-day study of oxalate absorption in subjects with secondary
      hyperoxaluria. Subjects visited the research center three times for outpatient visits
      (Screening, Test Day 3, Day 4).

      Subjects were instructed to follow a low-oxalate diet, consuming only study-specified food
      choices that had low or no oxalate and controlled calcium content Days 1 through 4 (Baseline
      Period through the Day 4 clinic visit) and, on Test Day 3, consumed an oxalate-rich test
      meal.

      Subjects performed three 24-hour urine collections during Screening, Baseline Day 2, and Test
      Day 3. Test Day 3 included the oxalate-rich test meal and the subject collected a 24-hour
      urine separated into 4 urine collection intervals. (Pre-test meal, post-test meal to 4 hours,
      4-6 hours post test meal and remaining time to complete 24 hours).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Oxalate Absorption Normalized by Baseline Urinary Oxalate Excretion Over a 24 Hour Test Period</measure>
    <time_frame>24 hours during baseline and test day following oxalate-rich meal</time_frame>
    <description>Percent of oxalate absorption normalized by baseline was calculated by 100*[UOx/test - UOx/baseline]/Ox intake from the test meal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Oxalate Absorption By Test Interval</measure>
    <time_frame>0-4 hours post test meal, 0-6 hours post test meal, 0-24 hours post test meal</time_frame>
    <description>Percent of Oxalate absorption by test interval was calculated as the urinary oxalate excretions (mg) during the test interval divided by the amount of oxalate in the test meal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline for Urinary Oxalate to Creatinine Ratio by Test Interval</measure>
    <time_frame>24 hours during baseline, 0 to 4 hours post test meal, 0-6 hours post test meal, 6-24 hours post test meal, 0-24 hours post test meal</time_frame>
    <description>Urinary oxalate (UOx) excretion was normalized to units of mg/g creatinine by dividing the UOx in mg by the creatinine value in g from the same collection. Percent change from baseline for UOx/Cr from Baseline was calculated by 100 * [UOx/Cr for the test interval - UOx/Cr at Baseline] / UOx/Cr at Baseline.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Secondary Hyperoxaluria</condition>
  <condition>Nephrolithiasis</condition>
  <condition>Hyperoxaluria</condition>
  <condition>Kidney Stones</condition>
  <arm_group>
    <arm_group_label>Test Meal</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>controlled oxalate-rich test meal</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Test Meal</intervention_name>
    <arm_group_label>Test Meal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or non-pregnant and non-lactating females

          -  History of hyperoxaluria secondary to a known underlying enteric disease (e.g.,
             Crohn's disease, bariatric surgery, and others) or without a known underlying cause
             (idiopathic), and kidney stones.

          -  Urinary oxalate â‰¥ 40 mg of oxalate/24 hr at screening.

          -  If taking drugs for the prevention of stone disease, including pyridoxine, thiazides
             (chlorthalidone, hydrochlorothiazide, and indapamide), citrate supplements, and
             allopurinol, there must have been no changes in these medications for at least one
             month prior to screening and no changes are anticipated for the duration of the study.

          -  Able to understand and provide written informed consent.

        Exclusion Criteria:

          -  Under or over-collection on screening 24-hour urine collection (mg creatinine/kg body
             weight outside of gender-specific range).

          -  Estimated glomerular filtration rate (eGFR) &lt;40 mL/minute/1.73 m^2 or acute renal
             failure.

          -  Primary hyperoxaluria.

          -  Allergy, intolerance, or any other factors limiting ability to consume the study foods
             or adhere to the study meal schedule.

          -  Positive pregnancy test during Screening.

          -  Clinically significant findings (including acute renal colic), an ongoing clinically
             significant illness requiring changes in management, or any planned medical/surgical
             procedure during the study.

          -  Malignancy undergoing active therapy; patients in remission on chronic suppressive or
             maintenance therapies are not excluded.

          -  Investigational compound within 30 days prior to screening.

          -  Investigator determined that the subject would not be able to adhere or to complete
             the study procedures , or could not discontinue Vitamin C supplements, calcium
             supplements, or other medications that could interfere with oxalate absorption and/or
             excretion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annamaria Kausz, MD, MS</last_name>
    <role>Study Director</role>
    <affiliation>Allena Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Urological Associates of Southern Arizona, PC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Applied Research Center of Arkansas, Inc.</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Urology, LLC</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Medical Research</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology of Virginia</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 20, 2017</study_first_submitted>
  <study_first_submitted_qc>March 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2017</study_first_posted>
  <results_first_submitted>January 30, 2019</results_first_submitted>
  <results_first_submitted_qc>March 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 24, 2020</results_first_posted>
  <last_update_submitted>March 11, 2020</last_update_submitted>
  <last_update_submitted_qc>March 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urine Oxalate</keyword>
  <keyword>Nephrolithiasis</keyword>
  <keyword>Kidney Stones</keyword>
  <keyword>Hyperoxaluria</keyword>
  <keyword>Enteric Hyperoxaluria</keyword>
  <keyword>urological Diseases</keyword>
  <keyword>Kidney Diseases</keyword>
  <keyword>Dietary Oxalate</keyword>
  <keyword>Idiopathic Hyperoxaluria</keyword>
  <keyword>Oxalate Absorption</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Hyperoxaluria</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Test Meal</title>
          <description>controlled oxalate-rich test meal</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Enrolled Set</title>
          <description>The Enrolled Set included all subjects who were determined to be eligible for the study after screening assessments and were enrolled in the study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.3" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI (kg/m^2)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.45" spread="8.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estimated glomerular filtration rate</title>
          <units>mL/minute/1.73 /m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80.7" spread="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hyperoxaluria Classification</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Idiopathic Hyperoxaluria</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Enteric Hyperoxaluria</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Kidney Stone Episodes at Study Entry</title>
          <units>Episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5" spread="5.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Oxalate Absorption Normalized by Baseline Urinary Oxalate Excretion Over a 24 Hour Test Period</title>
        <description>Percent of oxalate absorption normalized by baseline was calculated by 100*[UOx/test - UOx/baseline]/Ox intake from the test meal.</description>
        <time_frame>24 hours during baseline and test day following oxalate-rich meal</time_frame>
        <population>Enrolled set which included all enrolled subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Test Meal</title>
            <description>controlled oxalate-rich test meal</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Oxalate Absorption Normalized by Baseline Urinary Oxalate Excretion Over a 24 Hour Test Period</title>
          <description>Percent of oxalate absorption normalized by baseline was calculated by 100*[UOx/test - UOx/baseline]/Ox intake from the test meal.</description>
          <population>Enrolled set which included all enrolled subjects</population>
          <units>percentage of oxalate absorption</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.84" spread="2.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Oxalate Absorption By Test Interval</title>
        <description>Percent of Oxalate absorption by test interval was calculated as the urinary oxalate excretions (mg) during the test interval divided by the amount of oxalate in the test meal.</description>
        <time_frame>0-4 hours post test meal, 0-6 hours post test meal, 0-24 hours post test meal</time_frame>
        <population>Enrolled set which included all enrolled subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Test Meal</title>
            <description>controlled oxalate-rich test meal</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Oxalate Absorption By Test Interval</title>
          <description>Percent of Oxalate absorption by test interval was calculated as the urinary oxalate excretions (mg) during the test interval divided by the amount of oxalate in the test meal.</description>
          <population>Enrolled set which included all enrolled subjects</population>
          <units>percentage of oxalate absorption</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0-4 Hours post test meal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0-6 hours post test meal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.55" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0-24 hours post test meal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.83" spread="3.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline for Urinary Oxalate to Creatinine Ratio by Test Interval</title>
        <description>Urinary oxalate (UOx) excretion was normalized to units of mg/g creatinine by dividing the UOx in mg by the creatinine value in g from the same collection. Percent change from baseline for UOx/Cr from Baseline was calculated by 100 * [UOx/Cr for the test interval - UOx/Cr at Baseline] / UOx/Cr at Baseline.</description>
        <time_frame>24 hours during baseline, 0 to 4 hours post test meal, 0-6 hours post test meal, 6-24 hours post test meal, 0-24 hours post test meal</time_frame>
        <population>Enrolled set which included all enrolled subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Test Meal</title>
            <description>controlled oxalate-rich test meal</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline for Urinary Oxalate to Creatinine Ratio by Test Interval</title>
          <description>Urinary oxalate (UOx) excretion was normalized to units of mg/g creatinine by dividing the UOx in mg by the creatinine value in g from the same collection. Percent change from baseline for UOx/Cr from Baseline was calculated by 100 * [UOx/Cr for the test interval - UOx/Cr at Baseline] / UOx/Cr at Baseline.</description>
          <population>Enrolled set which included all enrolled subjects</population>
          <units>Percentage of change of UOx/Cr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0-4 hours post test meal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.17" spread="93.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0-6 hours post test meal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.73" spread="100.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-24 hours post test meal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.39" spread="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0-24 hours post test meal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.14" spread="64.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>34 days (adverse events were recorded from the time of informed consent until the last study visit, and the screening period was approximately 30 days)</time_frame>
      <desc>Since no investigational product was administered; no drug-related adverse events (AEs) occurred. The investigator assessed AEs by intensity (severity) and causality in relation to the study intervention, which was the study diet. Any untoward symptoms or worsening of medical conditions reported during the study were recorded as AEs.</desc>
      <group_list>
        <group group_id="E1">
          <title>Test Meal</title>
          <description>controlled oxalate-rich test meal</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Trigger finger</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Allena Medical Affairs</name_or_title>
      <organization>Allena Pharmaceuticals, Inc</organization>
      <phone>6174674577</phone>
      <email>AllenaMedInfo@allenapharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

